screening. This test measures a panel of gene expression biomarkers from whole blood and utilizes machine learning algorithms to interpret the data, providing a positive or negative result. Clinical studies have demonstrated high inferred accuracy for women under 50 and overall. Syantra's Onco-ID™ platform aims to expand early cancer detection capabilities across multiple cancer types.